Your session is about to expire
← Back to Search
Sulindac for Reducing Breast Cancer Risk
Study Summary
This trial will test whether sulindac can help reduce breast density in postmenopausal women who are at increased risk of breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a negative test for hidden blood in your stool.My organs are functioning normally.I do not have serious stomach, bleeding, or heart problems.You are known to have a bad reaction to anti-inflammatory drugs.I have one breast without any history of cancer, radiation, or implants.I have gone through menopause.You have a fear of small spaces or cannot have a scan in a closed MRI machine.My breasts are classified as dense.I am at high risk for breast cancer due to abnormal tests, family history, or genetics.I take aspirin or another anti-inflammatory medication daily.I haven't taken hormone therapy like tamoxifen in the last year.I am on hormonal therapy with aromatase inhibitors.My high blood pressure is not under control.I use insulin to manage my diabetes.You smoke regularly.I am 70 years old or younger.
- Group 1: Sulindac
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this trial the inaugural attempt at a study of its kind?
"Currently, 4 experiments surrounding Sulindac are being conducted across 623 cities in 2 different countries. In 2013, Cancer Prevention Pharmaceuticals, Inc. commenced a Phase 3 trial with 1340 participants; since then 18334 additional trials have been finalized."
Could you elucidate the potential risks of taking Sulindac?
"Taking into consideration the Phase 2 nature of this trial, our team at Power estimated Sulindac's safety to be a score of 2 due to limited data on its efficacy."
What is the maximum number of participants for this experiment?
"Affirmative. According to clinicaltrials.gov, this medical trial continues its search for 150 participants at two different locations since it was first posted on November 20th 2020 and edited more recently on February 23rd 2022."
In what conditions is Sulindac typically prescribed?
"Generally, sulindac is utilized to manage acute subacromial bursitis. Additionally, the drug has been demonstrated to be effective for cases of osteoarthritis (OA), acute supraspinatus tendinitis, and gouty arthritis."
Is enrollment for this research project still open?
"According to clinicaltrials.gov, this research project continues to search for additional participants since its first posting on November 20th 2020 and most recent update on February 23rd 2022."
Could you elucidate the past investigations that have utilized Sulindac?
"In 2013, Lake Norman Hematology Oncology Specialists-Mooresville first began examining sulindac. Nowadays, there are 18334 completed trials and 4 studies in the process of recruitment; many of these involve Stony Brook University's New york campus."
Share this study with friends
Copy Link
Messenger